Drug intelligence / Profile preview

PMG1019

Development stage: Preclinical
Lead developer: Pulmongene

Overview

PMG1019 is an investigational therapeutic candidate currently in the discovery stage of development by Pulmongene. It is being developed for the treatment of various autoimmune diseases. As of current public disclosures, Pulmongene has not revealed the specific molecular target, modality, or mechanism of action for this candidate. The program is part of a broader pipeline at Pulmongene that focuses on inflammatory and fibrotic conditions, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Beyond the preview

Go deeper on PMG1019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMG1019.

Explore the full profile